ETON News and Press, Eton Pharmaceutcials Inc.

2024-07-16 07:26:43 ET More on Eton Pharmaceuticals Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Eton Pharmaceuticals Historical earnings data for Eton Pharmaceuticals Financial information for Eton Pharma...

- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innov...

2024-05-11 09:34:08 ET Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript May 9, 2024 04:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference...

2024-05-09 16:42:48 ET More on Eton Pharmaceuticals Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript Relief Therapeutics grants exclusive U.S. rights to Eton Pharmaceuticals for PKU GOLIKE Seeking Alpha’s Quant Rating on Eton Pharmaceuticals ...

•  Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth •  Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

2024-05-08 14:37:36 ET More on Eton Pharmaceuticals Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript Relief Therapeutics grants exclusive U.S. rights to Eton Pharmaceuticals for PKU GOLIKE Seeking Alpha’s Quant Rating on Eton Pharmaceuticals ...

2024-05-06 09:00:05 ET Chase Knickerbocker from Craig-Hallum issued a price target of $8.00 for ETON on 2024-05-06 07:29:00. The adjusted price target was set to $8.00. At the time of the announcement, ETON was trading at $3.71. The overall price target consensus is at $...

DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial...

- Company anticipates 10-month review for potential approval in Q1 2025 - - Eton expects ET-400 and Alkindi Sprinkle ® to achieve potential combined peak sales of more than $50 million annually - - Product has patent protection through 2043 - DEER PARK, Ill., April 30, 2024 (GLOB...